Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry

Familial hypercholesterolemia (FH) is amongst the most common genetic disorders encountered in primary care. Yet, only a minority of affected patients is diagnosed and treated. This interim analysis of the CaRe High Registry aims at examining the state of treatment and attainment of lipid goals in G...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2018-10, Vol.277, p.314-322
Main Authors: Schmidt, Nina, Dressel, Alexander, Grammer, Tanja B., Gouni-Berthold, Ioanna, Julius, Ulrich, Kassner, Ursula, Klose, Gerald, König, Christel, Koenig, Wolfgang, Otte, Britta, Parhofer, Klaus G., Reinhard, Wibke, Schatz, Ulrike, Schunkert, Heribert, Steinhagen-Thiessen, Elisabeth, Vogt, Anja, Laufs, Ulrich, März, Winfried
Format: Article
Language:English
Subjects:
CaRe High registry
Familial hypercholesterolemia
LDL-C goal attainment
PCSK9 inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Familial hypercholesterolemia (FH) is amongst the most common genetic disorders encountered in primary care. Yet, only a minority of affected patients is diagnosed and treated. This interim analysis of the CaRe High Registry aims at examining the state of treatment and attainment of lipid goals in German FH patients. The CaRe High registry includes FH patients from lipid clinics and private practices. Data have been collected using questionnaires filled in by the recruiting physicians and by interviewing the participating patients. We examined 512 F H patients diagnosed according to clinical criteria. Median age at the time of the first FH diagnosis was 39 (25th and 75th percentile: 27–50) years, median treatment naïve LDL cholesterol (LDL-C) was 239.4 mg/dl (6.19 mmol/l), 25th to 75th percentile 191.8–342.5 mg/dl (4.96–8.86 mmol/l). 27% of the participants did not receive lipid-lowering drugs. Among the patients treated with lipid-lowering drugs, 19% received a PCSK9 inhibitor (PCSK9i) in combination with a statin, 9% were treated with a PCSK9i alone and 3% were treated with a combination of PCSK9i and a non-statin drug. Patients with pre-existing CVD were more likely to be treated with lipid-lowering drugs and more likely to receive a PCSK9i, but LDL-C targets were only achieved by a minority of patients (
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2018.08.050